Citi opened a “positive 90-day catalyst watch” on shares of Structure Therapeutics (GPCR) while keeping a Buy rating on the name with a $60 price target Citi views Structure’s risk/reward into the Phase 2b ACCESS and ACCESS II data for aleniglipron, expected by the end of 2025, as favorable.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Strong Market Demand and Convenience Drive Buy Rating for Structure Therapeutics
- Buy Rating for Structure Therapeutics: Aleniglipron’s Market Potential and Acquisition Appeal
- Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
- Optimistic Buy Rating for Structure Therapeutics Driven by Aleniglipron’s Potential in Obesity and T2D Markets